Pediatric medulloblastoma is considered a highly heterogeneous disease and a new strategy of risk stratification to optimize therapeutic outcomes is required. We aimed to investigate a new risk-stratification approach based on expression profiles of medulloblastoma cohorts. We analyzed gene expression profiles of 30 primary medulloblastomas and detected strong evidence that poor survival outcome was significantly associated with mRNA expression profiles of 17p loss. However, it was not supported in independent cohorts from previously published data (n 5 100). We speculated that this discrepancy might come from complex conditions of two important prognostic determinants: loss of tumor suppressors (chromosome 17p) and high expression of oncogenes c-myc (MYCC) or N-myc (MYCN). When patients were stratified into 5 or 7 subgroups based on simultaneous consideration of these 2 factors while defining the Wnt group as independent, obviously different survival expectancies were detected between the subgroups. For instance, predicted 5-year survival probabilities ranged from 19% to 81% in the 5 subgroups. We also found that age became a significant prognostic marker after adjusting for 17p, MYCC, and MYCN status. Diminished survival in age <3 years was more substantial in subgroups with high expression of MYCC, MYCN, or 17p loss but not in other subgroups, indicating that poor survival outcome might be synergistically affected by these 3 factors. Here we suggest a more tailored subgrouping system based on expression profiles of chromosome 17p, MYCC, and MYCN, which could provide the basis for a novel risk-stratification strategy in pediatric medulloblastoma.
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A s the most common malignant brain tumor in children, medulloblastoma comprises 15% to 20% of all pediatric primary brain tumors. 1 Advances in risk stratification and multimodal treatment have increased the 5-year overall survival rates considerably. 2 However, approximately 30% of patients remain incurable, and aggressive therapy often leads to severe long-term side effects in survivors. 3 Current treatment strategy is based on the risk-stratification system established by Packer et al, which categorizes patients into 2 groups: standard/average-risk and poor/high-risk group, according to presence of residual tumor larger than 1.5 cm 2 , age less than 3 years, and evidence of metastasis. 4 However, studies have shown that medulloblastoma is a highly heterogeneous disease, and a more refined risk-stratification system is required to minimize avoidable long-term adverse effects while maximizing the chance of survival. 5 Many genes and chromosomal aberrations have been identified as prognostic markers in medulloblastoma. The increased expression level of neurotrophin-3 receptor or tumor protein p73 6 -9 and positive nuclear staining of b-catenin (CTNNB1) 10, 11 were associated with good prognosis, and a low level of the histone acetyltransferase hMOF was associated with poor outcome of survival. 12 Conversely, unfavorable survival prognosis has been reported to be related to the elevated expression or amplification of c-myc (MYCC), N-myc (MYCN), c-erbB2/ neu, cyclin-dependent kinase 6, or serine/threonine kinase 15. 13 -19 Chromosomal aberrations are also frequently correlated with prognosis in medulloblastoma. Isochromosome 17q or 17p loss as well as gain of chromosome 17q, 1q, or 6q have been proposed as negative prognostic markers, 14, 17, 20, 21 whereas loss of chromosome 6 (monosomy 6) with activated Wnt signaling is a positive prognostic marker. 22, 23 Expression profiling of medulloblastoma also identified gene expression signatures associated with metastasis or patient prognosis. 19, 24 More recently, integrated genomics has revealed several distinct subclasses of medulloblastoma. 22, 23, 25, 26 One subgroup is characterized by activated sonic hedgehog (SHH) signaling enriched for patients with the desmoplastic subtype or younger age, containing Patched or suppressor of fused mutations. 27, 28 Another distinct subgroup that is often linked to favorable prognosis is marked by activated Wnt signaling with loss of chromosome 6 and CTNNB1 mutations. However, at least twothirds of medulloblastomas do not fall into these categories. There is therefore room for improvement in biological risk stratification. Moreover, detailed subclassification with appropriately selected prognostic markers enables the development of new risk-stratification strategies. For instance, precise prediction of prognosis becomes more crucial in high-dose chemotherapy followed by peripheral blood stem cell rescue therapy for a compatible high-risk group of patients. Several multigene-based predictors have already been commercialized in breast cancer, 29, 30 which ultimately provide the fundamentals for targeted therapy and personalized medicine.
In the present study, we investigated a new riskstratification approach based on a combined analysis of medulloblastoma cohorts and provide substantial evidence that concurrent consideration of chromosome 17p, MYCC, and MYCN might indicate a novel strategy for prediction of survival prognosis in medulloblastoma.
Materials and Methods

Patient Characteristics
Thirty medulloblastoma cases consisting of patients who were enrolled, diagnosed, and treated surgically at Seoul National University Children's Hospital (SNUCH) between 1998 and 2008 were evaluated. The details of treatment and follow-up were described in a previous study. 31 Clinical data were collected and analyzed with the approval of the Institutional Review Board of Seoul National University Hospital. Supplementary  Table S1 lists these clinical characteristics and their association with 2-year or 5-year survival status. The overall median follow-up time was 51.5 months (range, 11 -101 mo). The 2-year survival rate of all 30 children was 83.3%. The 5-year survival rate was 54.2% for 24 eligible children excluding 6 whose 5-year survival status was not yet available. No significant difference in age or gender was found between the prolonged and poor survival groups (Supplementary Table S1 ).
mRNA Microarray Chip Processing and Analysis of Gene Expression Data
Total RNA was extracted using the Qiagen RNeasy Mini kit and was amplified and labeled according to the Affymetrix GeneChip Whole Transcript Sense Target Labeling protocol. The resultant labeled cDNA was hybridized to Affymetrix Human Gene 1.0 ST (state transformer) arrays. The scanned raw expression values were background-corrected, normalized, and summarized using robust multiarray averaging. 32 Analysis of differentially expressed genes (DEGs) was confined to 24 children whose 5-year survival status was available. Moderated t-statistics based on an empirical Bayesian approach were used. 33 For nonspecific filtering, probe sets with a standard deviation less than the midpoint of the shorth were excluded. 34 The Benjamini-Hochberg false discovery rate (BH FDR)-adjusted P-value was used to correct for multiple testing errors. 35 Expression values were standardized with the median and inter quartile range (IQR) of each probe set, and unsupervised hierarchical clustering analysis was performed using the Manhattan distance and the Ward algorithm. Statistical supports for the clustering were obtained by bootstrapping analysis and the approximate unbiased test. 36 Fisher exact test was used to assess the significance of association.
Array Comparative Genomic Hybridization
Array comparative genomic hybridization (CGH) on 15 medulloblastoma tissue samples was performed using the Agilent 180K array. Patient DNA was labeled with cyanine 3 ′ -deoxyuridine triphosphate (dUTP) and the reference sample, a pool of male samples (Promega), was labeled with cyanine 5 ′ -dUTP. After hybridization of labeled DNA and scanning of the microarray, background-corrected and dye-bias normalized raw log 2 - and the segmented log 2 ratios were further merged. 39 
Combined Analysis with Independent Medulloblastoma Cohorts
Expression data sets and clinical information from 3 independent cohorts were obtained as indicated in Cho et al. 25 Microarray data of normal brain were acquired from the National Center for Biotechnical Information Gene Expression Omnibus ftp site (accession numbers: GSE17757, GSE11882, GSE2361, and GSE13471). Data were preprocessed with robust multiarray averaging. Data sets from Kool et al 23 and Fattet et al 11 were preprocessed together because the same microarray platforms were used. Data from 2 patients who died within 1 month after surgery (A317 and MB117) were excluded to remove the possibility of poor survival from surgery-related complications. In total, 176 medulloblastomas, including 30 from SNUCH, were used for further subgrouping, and survival analysis was confined to 130 cases whose survival data were available.
Stratification of Patients with 17p, MYCC, and MYCN Status and Survival Analysis
For combined analysis of 3 data sets from different microarray platforms, the relative expression level of a certain gene or genes (ie, MYCC, MYCN, mean of MYCC and MYCN, or principal component [PC] 1 of 17p or Wnt signaling -related genes) was calculated for each patient as follows. In each given data set, the expression profile or PC1 value defining the minimum and maximum values was rescaled to the same range of values (0 to 1), which enabled the integration of expression data from 3 different microarray platforms without any changes in the original distribution of expression in a given data set ( Supplementary Fig. S1 ). Subsequently, a total of 176 patients were categorized into 5 or 7 subgroups according to the combination of 17p status, MYCC, and MYCN expression level. In both subgroupings, 17p status was divided into 2 categories-loss or no loss-which was determined by unsupervised clustering of the expression profiles of chromosome 17p. In the 7 subgroupings, final status of MYCC and MYCN was categorized into 3 levels: Figure S1 , there were gaps around the relative value of 0.7 in the distribution of MYCC expression, which might indicate 2 separate groups: high expression versus others. On the other hand, the cutoff value of 0.15 was used to define low (normal) expression of MYCC(N) because relative expression levels of MYCC(N) in most normal brains, excluding those from fetal or newborn babies, are confined to a narrow region with a relative expression level ,0.15 (graycolored squares in Fig. 2F and Supplementary  Fig. S10 ). Therefore, those 2 values were considered as reasonable cutoffs to divide the expression level of MYCC(N) into normal, medium, and high. In the 5 subgroupings, the status of MYCC and MYCN was divided into 2 levels: (i) high, with a relative level of MYCC(N) .0.5; (ii) low, with all the rest. Conversely, the Wnt group (the group with upregulated Wnt-related genes) was always predefined as an independent subgroup regardless of 17p and MYCC(N) status. Survival analysis was performed with data from 130 patients whose survival outcomes were available (Supplementary material). Kaplan -Meier analysis and log-rank tests were performed to evaluate differences in survival among defined subgroups. Multivariable Cox proportional hazard models were fitted according to 17p status and relative expression values of MYCC and MYCN, with or without adjustment of age, histology, and the presence of seeding (M stage: M0, no seeding; M+, seeding). All statistical analyses were performed using the R statistical software. 40 
Results
Molecular Stratification of Medulloblastoma According to Gene Expression Profiles
Based on previous reports that gene expression profiles can be used to successfully classify heterogeneous medulloblastoma into several genetically homogeneous subgroups, 22, 23 we performed unsupervised hierarchical clustering using 915 probe sets with the greatest expression variability (IQR . 1.0). Thirty medulloblastoma patients were categorized into 5 subclusters with statistical supports greater than a 95% bootstrap value ( Supplementary Fig. S2 ). Previously reported gene markers for each subtype 23, 25 confirmed 4 subgroups-MYC (c1), SHH (c3), photoreceptor (c5), and Wnt (c6)-out of 6 subgroups (c1 -c6) ( Supplementary  Fig. S3 ). 25 However, we failed to distinguish the neuronal (c2) from the mixed (c4) group, and patients were manually assigned to the c2 or c4 group based on the expression of cone-rod homeobox (CRX), which is considered to be a specific marker for the photoreceptor group. 25 More specifically, both c2 and c4 groups expressed neuronal/glutamatergic signatures, and there was considerable overlap between these 2 groups, but it was confirmed by immunostaining that tumors in the c4 group also expressed a photoreceptor/GABA (gamma-aminobutyric acid)ergic signature (CRX), which was the very reason that the c4 group was designated as a mixed group. 25 Based on this result, patients were assigned to the c4 group when the expression level of CRX was equal to or greater than the median expression of CRX in 13 patients. Despite considerably clear subclustering, the 5 clusters identified with unsupervised clustering did not associate significantly with 5-year or 2-year survival prognosis ( Supplementary Fig. S3 ), which might be due in part to the small sample size.
Chromosome 17p as a Prognostic Marker for a 5-year Survival Outcome
To detect genomic signatures that might be responsible for the 5-year prognosis in medulloblastoma, we identified DEGs with expression profiles of 24 patients from SNUCH whose 5-year survival status was available. The expression of 66 probe sets changed significantly in patients with poor survival outcomes when we applied the BH FDR method to correct for multiple testing errors at the 0.2 significance level (Supplementary Table S2 ). Notably, 63 out of 66 DEGs were down-regulated in patients with poor survival and located on chromosome 17p. These results imply that low expression of genes located on 17p may be a crucial determinant of poor prognosis in medulloblastoma. Because most DEGs corresponded to transcripts from 17p, we further investigated the association between expression changes of these transcripts and 5-year survival outcome. Hierarchical clustering of 17p transcripts from 30 medulloblastomas revealed a distinct cluster with 17p loss (Fig. 1A) . The clustering of the 17p-loss group was supported with 100% statistical approximately unbiased/bootstrapping values ( Supplementary Fig. S4 ). A highly significant association was observed between 5-year prognosis and the 2 clusters (P ¼ .00022; Fig. 1B ). Other clinical factors such as histology, 2-year survival outcome, and overall survival status were also related significantly to the clusters identified with expression profiles of chromosome 17p genes (Fig. 1B) . We compared expression profiles and genomic aberrations on chromosome 17 by applying array CGH on 15 representative samples selected from the 2 clusters, with particular focus on the patients grouped into the 17p-loss category. The expression patterns were found to be highly concordant with aberrations in copy number or aneuploidy ( Supplementary Fig. S5 ), which enabled the inference of aberrations of chromosome 17 in other samples on which array CGH was not performed (Fig. 1C and D) . Accordingly, 7 of 9 patients in the 17p-loss group displayed isochromosome 17q, whereas 2 patients showed 17p loss without 17q gain (MB_09 and MB_24), indicating that loss of this chromosome arm may be the main driving factor for poor prognosis in medulloblastoma. To investigate whether there is regional segregation of DEGs or informative genes that are responsible for the 5-year survival outcome, we calculated 3 numeric values related to the informativeness of each probe set on chromosome 17p and then plotted these values against their chromosomal location. We applied 3 parameters: the partial area under the receiver operator characteristic curve (pAUC; P ¼ .2), 41 2log 10 (P-value from Student's t-test), and the signal-to-noise ratio. 42 The plot shows that the informative genes are locally segregated at the distal region of 17p corresponding to 17p13 -17p12 loci ( Supplementary Fig. S6A ), which is congruent to the deleted region observed in 2 patients who showed poor prognosis and a minimal region of loss in 17p (Supplementary Fig. S6B ). The parallel coordinate (PC) plot revealed a discernible separation of the 17p-loss group with poor survival (Fig. 1E) . Consistently significant survival differences were detected when the patients were stratified based on hierarchical clustering of 17p transcripts (Fig. 1F) .
Independent Medulloblastoma Cohorts and Combined Analysis
The association between 5-year prognosis and 17p expression profiles was investigated with other medulloblastoma data. However, we found that a considerable proportion of the 17p-loss group showed a good 5-year prognosis (about 30%, 9/29), whereas approximately 40% (20/49) of the patients in the group without 17p loss exhibited a poor 5-year survival ( Fig. 2A and B) , indicating that 17p loss alone may not be the single major determinant of 5-year survival status for poor outcome as with SNUCH data. Subsequently, we focused on 3 children from the SNUCH data who were in the group without 17p loss but had poor 5-year survival (MB_01, MB_10, and MB_14; Fig. 1A) . One of these children (MB_01) exhibited very high MYCC expression (relative expression level: 0.94, the second highest level of MYCC), while another (MB_10) showed high expression of MYCN (relative expression level: 0.72, the fourth highest level of MYCN; Supplementary Fig. S3 and Supplementary Material). Assuming that the expression level of MYCC or MYCN is another driving factor for poor survival in medulloblastoma, we explored the relationship between 5-year survival status and MYCC and MYCN expression levels by plotting their relative expression levels along with those of normal brain (Fig. 2C-E) . Surprisingly, most patients with the same level of MYCC and MYCN expression as that of normal brain cells showed a very good 5-year survival outcome. In addition, the c1 -c6 subtypes defined previously 25 appeared to be segregated largely into some confined areas according to their relative expression levels of MYCC and MYCN, and the segregation was particularly prominent in SHH, Wnt, and MYC subtypes ( Fig. 2C-E, Supplementary Fig. S7-S9 ). The biplot of relative levels of the mean expressions of MYCC and MYCN and PC1 of 17p expression confirmed that 17p and MYCC(N) statuses are significant determinants of survival in medulloblastoma, clearly showing that patients with a low mean expression of MYCC and MYCN and no 17p loss have prolonged survival ( Fig. 2F; Supplementary Fig. S10 -S13 ). Chromosome 17p loss was detected in all subtypes (c1 -c6), and the proportion of 17p loss in each group ranged from 14.3% (SHH) to 67.5% (neuronal) when we excluded the Wnt subtype, where only 1 patient (A270) showed 17p loss ( Fig. 2A) . Kaplan -Meier curves and log-rank tests also confirmed the significant relationship between survival outcome and 17p and MYCC(N) status ( Supplementary Fig. S14 ).
New Stratification Based on Profiles of 17p, MYCC(N) and Wnt Signaling
When patients were stratified into 5 or 7 subgroups based on these 2 factors while defining the Wnt group as an independent subgroup regardless of 17p or MYCC(N) status (Fig. 3A and B) , significant survival differences were detected among subgroups in all ages, particularly in children aged 3 years or more ( Fig. 3C-F ; Supplementary Fig. S15 -S18 ). The new stratification clearly showed that 5-year survival outcome is correlated with 17p and MYCC(N) status (Fig. 3G) . Predicted 5-year survival probabilities ranged from 19% to 81% in the 5 subgroups (Table 1) . Survival was highest in patients with a normal range of MYCC(N) expression and no 17p loss ( Fig. 3C-G ; Table 1 ). No child aged ,3 years was found in the group with a normal range of MYCC(N) (relative expression level ≤0.15) or in the Wnt group ( Fig. 2C-E; Table 1 ), which possibly explains, in part, a previous report indicating that children aged ,3 years usually have poor prognosis. Moreover, multivariate Cox regression survival analysis showed that reduced survival was associated with age ,3 years, suggesting that age is one of the significant factors affecting survival outcome even after adjusting for MYCC, MYCN, and 17p status ( Table 2 ). In addition, when the data of children aged ,3 years were excluded, the predicted survival probability was increased, particularly in the 7HN (high MYCC(N)/no 17p loss) group of the 7 subgroups (Table 1 ). This implies that the effect Statistically significant difference between a given subgroup and all other subgroups (log-rank test; P , .05).
of age is modified by the status of MYCC(N) and chromosome 17p. Indeed, the unfavorable effect of young age is more aggressive in groups with poor prognostic markers, such as high MYCC(N) or 17p loss (Fig. 4) .
Discussion
Based on the analysis of large combined data from several independent cohorts, we found that chromosome 17p loss and the expression levels of MYCC and MYCN are significant determinants for survival in medulloblastoma. Considering these 2 factors simultaneously, we could stratify patients into subgroups with distinct survival. In the procedure of stratification, we defined in advance the Wnt group as independent based on a recent study that Wnt medulloblastoma is a distinct disease that arises in the dorsal brain stem and not in the cerebellum. 43 On the other hand, in multivariate modeling, age appeared to be another significant factor in the survival outcome of patients.
In many previous studies, chromosome 17p, MYCC, and MYCN have been observed to be significant prognostic factors in medulloblastoma. Amplified MYCC is often related to poor survival of patients. Recent molecular subtyping with a large medulloblastoma cohort also revealed a new poor prognostic subtype characterized by high expression of MYCC-related signatures. 25 Loss of chromosome 17p, frequently accompanied by gain of 17q (isochromosome 17q), is the most commonly detected chromosomal aberration in medulloblastoma, comprising 30% to 50% of all cases. 44 The breakpoint is known to be located in the proximal region of the short arm, 17p11. 45 -48 Several tumor suppressors, including p53, are located within the most commonly deleted region of 17p.
5 Consistent with this, many of the DEGs identified from the analysis of SNUCH data are putative or confirmed tumor suppressors and/or play crucial roles in life, such as neurogenesis, apoptosis, and maintenance of chromosomal integrity (Supplementary  Table  S3 ). Nevertheless, the importance of 17p or isochromosome 17q as a prognostic marker has been controversial. 15, 17, 20, 49, 50 We suspected that these controversies might have arisen from the interwoven conditions of 2 important prognostic determinants: loss of tumor suppressors (chromosome 17p) and high expression of oncogenes (MYCC or MYCN). On the other hand, 17q gain was also reported to be a significant poor prognostic marker in pediatric medulloblastoma. 14 However, in the SNUCH cohort, patients who had17q gain without 17p loss did not show poor 5-year survival (Fig. 1A-D) . To investigate further the significance of the overall status of chromosome 17 in prognosis, patients were stratified based on the unsupervised clustering of expression profiles of 17p and 17q (Fig. 1A-D, Supplementary Fig. S19 -S21) , and the survivals were compared between the groups. The results confirmed that 17p loss was a significant prognostic marker, clearly revealing that not only isochromosome 17q but also 17p loss alone were associated with poor outcome (Supplementary Fig. S22) , showing almost the same hazard ratio after adjusting for age and expression of MYCC and MYCN (Table 3) . However, 17q gain alone did not show statistically significant association with poor survival outcome (Table 3) .
Based on concurrent consideration of these 2 factors, we divided patients into new subgroups, estimating obviously different survival expectancies among them. This analysis could be performed not just by detecting amplified MYCC or MYCN status but by quantifying the expression level of MYCC and MYCN. The relationship between MYCC(N) and poor prognosis became more prominent after separation of the Wnt group from the medulloblastoma data set by reducing the confounding effect of the Wnt group because patients with high Wnt/b-catenin signaling are often linked to good prognosis despite their elevated expression of MYCC and MYCN, which are known downstream targets of Wnt signaling.
We also examined the expression levels of MYCC and MYCN according to histologic type (Supplementary Table S4, Fig. S23 ). It appeared that the proportion of high expression of MYCC (relative expression level .0.7 or .0.5) was higher in anaplasia than in the classic or desmoplastic type, which was more profound when Wnt medulloblastomas were excluded. This is congruent with previous reports that there is a correlation between anaplasia and MYCC amplification or overexpression. Conversely, however, the expression of MYCN was highest in the desmoplastic type when young children (,3 y) were excluded; the proportion with high expression in the desmoplastic type was diminished extensively, which indicates that most young children were included in the desmoplastic type showing high expression of MYCN.
Additionally, we found that age is a significant prognostic marker among the clinical characteristics after adjusting for 17p, MYCC, and MYCN status. In fact, age was not significantly associated with survival in univariate analysis (P ¼ .056; Supplementary  Fig. S24 ). However, stratified analysis revealed that diminished survival in patients aged ,3 years was profound in only the poor prognosis groups (ie, high MYCC(N) or 17p loss) but not in other groups, indicating that 3 negative prognostic factors-young age, high MYCC(N) expression, and 17p loss-might synergistically lead to poor survival outcome in medulloblastoma. Consistent with this, in a mouse model of primitive neuroectodermal tumors, tumor formation required not only activated MYCC but also loss of p53, suggesting that tumorigenesis can be induced by MYCC in the context of p53 loss. 51 In addition, MYCC is a transcription factor that plays a pivotal role in the control of cell proliferation and cell cycle progression, and its expression is deregulated in most forms of cancer. Strict regulation of MYCC levels and activities is critical to maintain normal cell physiology and is likely to be mediated, at least in part, by coregulators (ie, coactivators and corepressors). For example, MYCC expression and its transcriptional activity are negatively regulated by the corepressor NCOR1, 52, 53 and interestingly the NCOR1 gene is located on chromosome 17p11 and was detected as one of the DEGs responsible for 5-year survival in the analysis of SNUCH data (P-value ¼ .0016) ( Supplementary Table S2 ). Thus, loss of NCOR1 expression by deletion of chromosome 17p may result in uncontrolled MYCC expression and its transcriptional activity, thereby promoting malignant behavior of cancer cells and leading to poor outcome.
In conclusion, we suggest a more tailored subgrouping system based on expression profiles of chromosome 17p, MYCC, and MYCN, which could ultimately lead to the basis for a new risk-stratification strategy in medulloblastoma.
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